Cardioprotection induced by Na+/K+-ATPase activation involves extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt pathway

Cardiovascular Research

Volumn 89, Issue 1, 2011, Pages 51-59

  Zheng, Jin ^a   Koh, Xiuxian ^a   Hua, Fei ^a   Li, Guang ^a   Larrick, James W ^b   Bian, Jin Song ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Panorama Research Institute   (United States)

Author keywords

Antibody; Cardioprotection; Chronic heart failure; Na K ATPase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DR REGION SPECIFIC ANTIBODY; HERBIMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCLONAL ANTIBODY; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART PROTECTION; INOTROPISM; ISOLATED HEART; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; CARDIOTONIC AGENTS; ENZYME ACTIVATION; HEART FAILURE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC-FAMILY KINASES;

EID: 78650459913     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq263     Document Type: Article

References (40)

1. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-1889.
2. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002;87:235-241.
3. Gheorghiade M, Adams KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959-2964.
4. Skou JC. The Na,K-pump. Methods Enzymol 1988;156:1-25.
5. (+)-ATPase. J Biol Chem 1994;269:19659-19662.
6. + concentrations. J Biol Chem 2000;275:27838-27844.
7. +)-ATPase induces positive inotropy in intact mouse heart in vivo. Biochem Biophys Res Commun 2006;349: 582-587.
8. +)-ATPase. Biochem Biophys Res Commun 2005;338: 1669-1677.
9. + channel function. Mol Pharmacol 2009;75: 774-781.
10. Tian J, Liu J, Garlid KD, Shapiro JI, Xie Z. Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial K(ATP) channels. Mol Cell Biochem 2003;242:181-187.
11. +-ATPase signaling cascade in rat hearts. Cardiovasc Res 2007;73:488-496.
12. Jorgensen P. Purification and characterization of the Na-K ATPase from outer medulla of mammalian kidney. Biochem Biophys Acta 1974;336:36-52.
13. Kyte J. Purificationof the sodium- and potassium-dependent adenosine triphosphatase from canine renal medulla. J Biol Chem 1971;246:4157-4165.
14. Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S et al. Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther 2006;316:670-678.
15. Hu LF, Pan TT, Neo KL, Yong QC, Bian JS. Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardio-myocytes. Pflugers Arch 2008;455:971-978.
16. Macianskiene R, Matejovic P, Sipido K, Flameng W, Mubagwa K. Modulation of the extracellular divalent cation-inhibited non-selective conductance in cardiac cells by metabolic inhibition and by oxidants. J Mol Cell Cardiol 2001;33:1371-1385.
17. Otter D, Austin C. Hypoxia, metabolic inhibition, and isolated rat mesenteric tone: influence of arterial diameter. Microvasc Res 2000;59:107-114.
18. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 2003;3:157-168.
19. +-ATPase. J Biol Chem 2004;279:17250-17259.
20. +-ATPase. J Biol Chem 2000;275: 27832-27837.
21. Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear events. Oncogene 2007;26:3240-3253.
22. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Onco-gene 2007;26:3100-3112.
23. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC et al. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000;86:692-699.
24. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postcon-ditioning. Cardiovasc Res 2006;70:240-253.
25. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, Fisher PB. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008;27: 1114-1121.
26. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
27. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-605.
28. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996;8:168-173.
29. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279:L429-L438.
30. Gutcher I, Webb PR, Anderson NG. The isoform-specific regulation of apoptosis by protein kinase C. Cell Mol Life Sci 2003;60:1061-1070.
31. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-294.
32. Bian JS, Wang HX, Zhang WM, Wong TM. Effects of kappa-opioid receptor stimulation in the heart and the involvement of protein kinase C. Br J Pharmacol 1998; 124:600-606.
33. Pan TT, Neo KL, Hu LF, Yong QC, Bian JS. H2S preconditioning-induced PKC activation regulates intracellular calcium handling in rat cardiomyocytes. Am J Physiol Cell Physiol 2008;294:C169-C177.
34. Pan TT, Yong QC, Bain JS. All in the timing: a comparison between the cardioprotec-tion induced by H2S preconditioning and post-infarction treatment. Eur J Pharmacol 2009;616:160-165.
35. Matsumura K, Komori S, Takusagawa M, Osada M, Tanabe F, Itoh M et al. Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. Mol Cell Biochem 2000;214: 39-45.
36. Moon CH, Jung YS, Lee SH, Baik EJ. Protein kinase C inhibitors abolish the increased resistance of diabetic rat heart to ischemia-reperfusion injury. Jpn J Physiol 1999;49: 409-415.
37. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res 1994;75:586-590.
38. Cameron AJ, Procyk KJ, Leitges M, Parker PJ. PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer 2008;123:769-779.
39. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) iso-forms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and che-motherapeutic resistance. Cancer Res 2003;634:780-786.
40. McCracken MA, Miraglia LJ, McKay RA, Strobl JS. Protein kinase C delta is a prosur-vival factor in human breast tumor cell lines. Mol Cancer Ther 2003;2:273-281.